Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the United Kingdom (UK), showing that a high level of efficacy for its protein-based Covid-19 vaccine, was maintained over a 6-month period of surveillance. Additionally, the analysis showed vaccine efficacy of 82.5% in protection against all Covid-19 infections – both symptomatic and asymptomatic – as measured by PCR+ or anti-N seroconversion.

"These data have two implications for NVX-CoV2373. Importantly, the vaccine offers protection against symptomatic and asymptomatic Covid-19 infection which may both interrupt virus transmission and prevent Covid-19 disease," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "Additionally, we are encouraged to see that our vaccine maintains a high level of durable efficacy and continues to exhibit a reassuring safety profile in this extended timeframe."

The data build upon the final analysis of the UK Phase 3 trial, published in the New England Journal of Medicine in June 2021, which was used as part of Novavax' regulatory submissions for NVX-CoV2373 around the world and demonstrated a vaccine efficacy of 89.7% with cases collected over three months (median of 55 days of surveillance).